Last reviewed · How we verify
GR1802 injection
GR1802 injection is a monoclonal antibody targeting the PD-1 receptor.
GR1802 injection is a monoclonal antibody targeting the PD-1 receptor. Used for Non-small cell lung cancer, PD-L1 positive.
At a glance
| Generic name | GR1802 injection |
|---|---|
| Sponsor | Genrix (Shanghai) Biopharmaceutical Co., Ltd. |
| Drug class | PD-1 inhibitor |
| Target | PD-1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
By binding to PD-1, GR1802 injection blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby releasing the brakes on T-cell activation and proliferation, leading to enhanced anti-tumor immune responses.
Approved indications
- Non-small cell lung cancer, PD-L1 positive
Common side effects
- Fatigue
- Diarrhea
- Nausea
- Rash
- Pyrexia
Key clinical trials
- A Study of GR1802 Injection in Patients With Seasonal Allergic Rhinitis. (PHASE3)
- A Study of IL4Rα Monoclonal Antibody in Patients With Seasonal Allergic Rhinitis (PHASE3)
- A Study of IL4Rα Monoclonal Antibody in Patients With Seasonal Allergic Rhinitis(SAR). (PHASE2)
- A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase II Trail Evaluating the Efficacy and Safety of GR1802 Injection in Patients with Moderate to Severe Asthma (PHASE2)
- The Study of GR1802 in Patients with Chronic Rhinosinusitis with Nasal Polyps (PHASE2)
- Phase III Study of GR1802 Injection in Patients With Atopic Dermatitis (PHASE3)
- The Study of Long-term Outcomes of GR1802 in Patients With Chronic Rhinosinusitis With Nasal Polyps (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GR1802 injection CI brief — competitive landscape report
- GR1802 injection updates RSS · CI watch RSS
- Genrix (Shanghai) Biopharmaceutical Co., Ltd. portfolio CI